Extremely significant positive changes in Puma Biotechnology Inc (NASDAQ: PBYI) investment behavior have recently occurred: its shorter term price trend turned up, and the stock’s recent price rise disrupted its longer term downtrend.
Recent notable positive changes in fundamentals have benefitted Puma Biotechnology Inc (NASDAQ: PBYI): the consensus estimate for December, 2024 increased significantly, and the consensus estimate for December, 2023 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
PBYI is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Puma Biotechnology has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Puma Biotechnology has a slightly positive Appreciation Score of 61 and a slightly positive Power Rating of 69, producing the Positive Value Trend Rating.
Recent Price Action
Puma Biotechnology Inc (NASDAQ: PBYI) stock suffered a large decline of -3.5% on 11/17/23. The stock closed at $3.85. Relative to the market the stock has been strong over the last nine months and has risen 16.3% during the last week.